Immunotherapy targets in pediatric cancer

Rimas J. Orentas *, Daniel W. Lee and Crystal Mackall *

Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Keywords: immunotherapy, tumor antigens, pediatric cancer, adoptive immunotherapy, chimeric antigen receptor, antibody therapy, tumor immunity

PRINCIPLES GUIDING SELECTION OF TARGETS FOR IMMUNOTHERAPY OF CANCER

Improved outcomes for childhood cancer rests upon the development of new, targeted therapies to kill tumor cells. Much work has focused on targeting oncogenes mediating growth pathways to which the tumor has become “addicted” (Diehl et al., 2007; Sharma and Settleman, 2007; Weinstein and Joe, 2008). This strategy has yielded some impressive results, including the development of ABL inhibitors for chronic myeloid leukemia (Cortes et al., 2011), KIT inhibitors for gastrointestinal stromal tumor, and BRAF inhibitors for melanoma (Dhomen and Marais, 2009; Ribas and Flaherty, 2011). However, not uncommonly, oncogene inhibitors fail to mediate significant antitumor effects due to redundant growth/survival pathways that bypass the targeted pathway (e.g., FLT3 inhibitors in acute myeloid leukemia, EGFR inhibitors in lung cancer; Diehl et al., 2007; Christoffersen et al., 2009; Normanno et al., 2009; Siena et al., 2009). For this reason, oncogene-inhibition has not yet assumed a major role in the treatment of pediatric cancers.

An alternative paradigm for targeted cancer therapy utilizes immune based therapies where the principles underlying target selection differ in some ways from those driving selection of oncogene-inhibition targets (Cheever et al., 2009). Most notably, while oncogene-inhibition targets must mediate non-redundant growth/survival pathways, immune targets need not play a significant role in the life or death of the cancer cell since they serve only to direct immune effectors to the tumor cell. Selection of antigen negative variants can occur when targeting non-essential molecules (Czerniecki et al., 2007; Sampson et al., 2010), but thus far this has not been the major factor limiting the effectiveness of immune based therapies (Smith, 2003). Thus, while it is desirable for immune targets to be involved in tumor growth/survival, this is not a requirement.

A second area whereby target selection for oncogene-inhibition differs from immunotherapy relates to the importance of tumor-specific mutations. Mutated genes are compelling targets for oncogene-inhibition since they implicate the target as a “driver” in oncogenesis, and mutated kinases can be specifically targeted with small molecules. For immune based targeting, mutated targets present both opportunities and challenges. Tumor-specific mutations are predicted to be more immunogenic than non-mutated molecules, since immune tolerance to somatically mutated molecules is not induced during normal development. Consistent with this, early encouraging results have been reported with a vaccine targeting EGFRvIII, a mutated EGFR in gliomas (Sampson et al., 2010). But, the corollary is that the number of epitopes generated by most mutations is small, and the likelihood that any one epitope will be immunogenic is also very small. Because most mutated molecules in cancer reside intracellularly and can only be recognized by MHC restricted T cell receptors, the epitopes that are “immunogenic” will be so only in the fraction of the population expressing the appropriate MHC allele. For example, the breakpoint regions of PAX3–FKHR (van den Broeke et al., 2006) and SYS–SSX2 (Worley et al., 2001) are predicted to be immunogenic in HLA–B7 + individuals, which comprise only approximately 15% of the population. Immune therapies that target one epitope present in only a small fraction of the population are difficult to standardize and translate into off-the-shelf therapies. Thus, very few tumor-specific mutations have been targeted successfully via immunotherapy.

Despite these challenges, the likelihood that immunogenic epitopes are present in any individual cancer increases with an
increase in mutation frequency. Carcinomas are estimated to carry, on average, 7–10 unique, novel mutations capable of being recognized by the immune system (Segal et al., 2008). Such “tumor-specific” immunogenicity was directly demonstrated in early studies of carcinogen induced sarcomas wherein tumor-specific immunity in individual tumor bearing mice was not found in genetically identical littermates bearing tumors of the same histology, presumably due to the presence of unique tumor-specific mutations in individual tumors (Wortzel et al., 1983). This concept of “private antigens” provides rationale for patient-specific immunotherapies such as whole cell vaccines, and/or broad based immunomodulators such as anti-CTLA4 or anti-PD1, which can augment immunity to “personal epitopes” and result in meaningful antitumor effects across populations, albeit to different epitopes in different individuals (Peggs et al., 2006; Ascierto et al., 2010).

A third point to consider when selecting immune based targets relates to exclusivity of tumor expression. Tumor exclusivity is desirable but rare, and target expression on some normal tissues is not necessarily a barrier to immune based targeting. Many successful immune targets display some normal tissue expression, including cancer–testis antigens that are also expressed on testicular germ cells, prostate specific antigen, and prostate acid phosphatase expressed in normal prostatic tissue, gp100, and tyrosinase expressed by normal melanocytes, and CD19, CD20, and CD22 expressed by normal B-cells. Normal tissue expression does however carry the risk of on-target, off-tumor effects, as evidenced by vitiligo following immunotherapy for melanoma due to damage to normal melanocytes (Turk et al., 2002; Luiten et al., 2005; Gogas et al., 2006), and loss of normal B-cells when targeting B-cell antigens (Kochenderfer et al., 2010). High-level expression can also limit the effectiveness of immunotherapy by inducing immune tolerance or by competing with the tumor target. Moreover, even limited non-tumor expression on vital organs can lead to unacceptable toxicity. Thus, optimal immune based targets do not necessarily require tumor exclusivity, but should have limited normal tissue expression that does not include cells required for maintaining vital tissue or organ functions.

Working from these fundamental principles, this manuscript will discuss candidate targets for immune based therapies of childhood cancers, including cell surface antigens suitable for non-MHC restricted targeting as well as MHC restricted T cell targets.

**CELL SURFACE ANTIGENS: NON-MHC RESTRICTED IMMUNE TARGETS IN PEDIATRIC CANCER**

Immune based targeting of tumor cell surface molecules can utilize native antibodies, antibody-derived molecules linked to drugs, toxins, or radioactive isotopes, bi-specific antibodies that recruit effector immune cells (Baeuerle and Reinhardt, 2009), or T or NK cells genetically engineered to express a receptor that recognizes the antigen. Recently affinity-matured oligonucleotide structures, termed aptamers, have been used to target the tumor cell surface as well (Pastor et al., 2011). Regardless of the approach used, one compelling feature of targeting cell surface antigens in pediatric cancers is the lack of MHC restriction, which renders therapies applicable to all patients expressing the antigen on their tumor cells, regardless of MHC allele expression.

Historically, monoclonal antibodies, or their derivatives, could only passively target cell surface antigens, mediating antitumor effects only as long as the antibody was present. T cell based therapies, in contrast could mediate active immunotherapy, since they had the potential for in vivo expansion, long-term persistence, and immune memory. These advantages of T cell based therapies, however, were offset by limitations posed by MHC restriction, where any particular antigen could only be targeted in individuals with a particular MHC allele. The development of chimeric antigen receptors (CARs), which endow T cells with the reactivity of a monoclonal antibody, combines the benefits of T cell based therapy but with MHC independence (Figure 1). For these reasons, many are optimistic that CARs will ultimately prove to be effective, off-the-shelf reagents with broad applicability in cancer (Urba and Longo, 2011). The fact that academia can generate these therapies, without the large scale pharmaceutical investment required for small molecule oncogene inhibitors, further enhances the attractiveness of this approach for targeting rare cancers, such as those occurring in children. For a detailed discussion of the current strategies and challenges facing CAR-based immunotherapy, please see Lee DW et al., Clinical Cancer Research (In Press). Below is a summary of cell surface molecules expressed by pediatric cancers that are candidates for immune based targeting. Those targets that are the focus of substantial current research are discussed in the text, while a more complete listing is provided in Table 1.

**CANDIDATE CELL SURFACE IMMUNE TARGETS EXPRESSED ON HEMATOLOGIC MALIGNANCIES OF CHILDHOOD**

**CD19**

CD19 is an ideal immune target, being universally expressed by acute lymphoblastic leukemia, the most common malignancy of children, whereas expression on non-tumor tissues is restricted to B-cells and their progenitors but not hematopoietic stem cells (Nadler et al., 1983, 1984). Despite this favorable tissue distribution, early studies with unconjugated anti-CD19 monoclonal antibodies and anti-CD19 immunotoxins against CD19+ lymphomas were ineffective (Stone et al., 1996; Furman et al., 2011; Schindler et al., 2011). Recently however, a variety of new therapies targeting CD19 have shown promise. Blinatumomab (anti-CD19 BiTE) is a bi-specific antibody that binds CD19 and CD3, thus activating T cells in close proximity to CD19+ lymphoblasts. This agent showed antitumor activity in adults with B-cell lymphoma (Bargou et al., 2008), and in adult ALL patients treated with minimal residual disease, 16/21 patients had clearance of leukemia after blinatumomab monotherapy (Topp et al., 2011). Of four patients who suffered a relapse following blinatumomab, two were in sanctuary sites (testis, brain), and two relapsed with CD19+ ALL, suggesting that tissue penetration and the development of antigen negative variants could pose a challenge for monotherapy with this agent (Topp et al., 2011). Reversible neurotoxicity was also observed in two patients (Topp et al., 2011). A Phase II trial enrolling adult patients with relapsed/refractory adult ALL with at least 5% bone marrow blasts is currently underway (NCT01209286), but pediatric studies have not yet been initiated.

Anti-CD19 CAR therapies have also induced robust clinical responses in CD19 expressing malignancies. Remissions have now been documented in refractory B-cell lymphoma and CLL after administration of lymphodepleting chemotherapy followed by infusion of T cells transduced to express anti-CD19 CAR (Kochenderfer et al., 2010; Kalos et al., 2011; Porter et al., 2011). These
FIGURE 1 | Chimeric antigen receptors provide for expanded targeting opportunities compared to T cell receptors. Chimeric antigen receptors (CARs) combine a variety of antigen-recognition strategies with the functionality of the T cell receptor and a co-stimulatory signal (i.e., Signal 2) and eliminates MHC restriction. This potentially allows for the targeting of any extracellular moiety such as signaling or cytokine receptors, cell adhesion molecules, gangliosides, or other proteins communicating with the extracellular matrix. In contrast, the classic T cell receptor recognizes processed peptides in the context of MHC providing a strategy for targeting intracellular, immunogenic antigens.

studies provide proof-of-principle that anti-CD19 CAR therapies can mediate impressive antitumor effects. Yet many questions remain regarding the optimal methods for generating CAR T cells, optimal preparative regimens, whether concurrent cytokine therapy improves outcomes and the relative importance of specific T cell subsets in mediating antitumor effects. Two pediatric studies are currently using anti-CD19 CARs to treat ALL (NCT00840853 and NCT01430390). Both administer virus-specific T cells transduced with the anti-CD19 CAR, an approach that substantially extends the time it takes to generate the cells, but could translate into improved persistence as demonstrated using GD2–CAR T cells (Pule et al., 2008). While the elimination of normal B-cells has been observed in adult CD19 CAR trials similar to patients who receive the anti-CD20 monoclonal antibody, rituximab, patients tend to tolerate this on-target side effect with appropriate supportive care. In fact, the constant production of B-cells by CD19− progenitors may provide chronic, low-level stimulation to transferred anti-CD19 CAR T cells thereby potentially contributing to persistence and long-term surveillance for leukemia relapse. It is anticipated that several more trials will open soon using anti-CD19 CAR T cells to treat pediatric ALL, using a variety of CAR constructs, T cell populations and treatment schemas.

CD22

CD22 is also universally expressed on pediatric ALL blasts and its expression is also restricted to the B-cell compartment (Campana et al., 1985; Gudowius et al., 2006). Epratuzumab, an unconjugated anti-CD22 antibody, was not sufficient as a single agent to achieve clinical responses in pediatric ALL, but when combined with four-drug re-induction chemotherapy 9/18 patients achieved a CR with seven of those nine MRD negative (Raetz et al., 2008). Phase II studies of epratuzumab alone and in combination with other chemotherapy regimens and haploidentical NK cell infusions are underway. Because CD22 is efficiently internalized (in contrast to CD19; Chan et al., 1998) and since internalization is important for the efficacy of immunotoxins, there has also been substantial interest in the development of anti-CD22 immunotoxins. Moxetumomab pasudotox, a high-affinity anti-CD22 antibody conjugated to pseudomonas exotoxin, has induced complete responses in 4/17 (24%) patients with refractory and relapsed pediatric ALL and most patients showed evidence for antitumor activity with little toxicity (Wayne et al., 2010; NCT00659425). Inotuzumab ozogamicin is another anti-CD22 immunotoxin also under study in patients 16 years of age and older with ALL and B-cell lymphoma (NCT01134575). This immunotoxin uses the same calicheamicin derivative found in Mylotarg (gemtuzumab ozogamicin).

Combotox, a 1:1 mixture of anti-CD19 and anti-CD22 antibodies conjugated to deglycosylated ricin-A chain has recently shown hematologic activity in 10/17 children with refractory ALL, of which three were complete responses (Herrera et al., 2009). Similarly, hematologic activity was observed in adults with ALL, although dose limiting capillary leak syndrome was observed (Schindler et al., 2011). Combotox is currently being investigated in adult ALL to determine the MTD when co-administered with 3 days of high-dose cytarabine (4 g/m²/day; NCT01408160). DT2219ARL is another bi-specific antibody targeting CD19 and CD22 that is conjugated to diphtheria toxin and is also currently under study in pediatric ALL (NCT00889408; Vallera et al., 2009). Finally, anti-CD22 CAR T cell therapy is being actively pursued with some preclinical activity reported (James et al., 2008).
| IT target | Tumor expression | Normal expression | Comments | References |
|-----------|------------------|-------------------|----------|-----------|
| CD20      | PTLD, B-cell lymphomas, CLL | Late pro-B-cells through B-cells Not before late pro-B-cells or on plasma cells | May be upregulated on pre-B ALL with chemotherapy, steroids NCT01363128; NCT01279707 | Coiffier et al. (2002), Thomas et al. (2006), Kumar et al. (2011), Meinhardt et al. (2010), Woyach et al. (2011), Evens et al. (2010), Jeha et al. (2006), Piccaluga et al. (2010), Gaipa et al. (2005), Dworzak et al. (2008) |
| CD19      | Pre-B ALL, B-cell lymphomas, CLL | Early pro-B-cells through mature B-cells Not before early pro-B-cells or on plasma cells | Promising early results using CARs NCT01209286; NCT00840853; NCT01430390 | Kochenderfer et al. (2010), Nadler et al. (1983, 1984), Kalos et al. (2011), Porter et al. (2011) |
| CD22      | Pre-B ALL, B-cell lymphomas, CLL | Early pro-B-cells through mature B-cells Not before early pro-B-cells or on plasma cells | Internalization facilitates toxin delivery NCT00659425; NCT01134575; NCT00889408 | Campagna et al. (1985), Gudowius et al. (2006), Chan et al. (1998) |
| CD30      | Hodgkin’s lymphoma, ALCL | Activated T and B-cells NCT0192464; NCT01316146 | | Stein et al. (1985), Leoncini et al. (1990), Kennedy et al. (2006) |
| CD52      | 100% T cell ALL 81% Pre-B ALL (except MLL) | B-cells, T cells, NK cells, monocytes, macrophages, dendritic cells, T cell progenitors Alemtuzumab has significant on-target, off-tissue toxicity NCT00061945; NCT00983528 | | Piccaluga et al. (2010), Tang et al. (1996) |
| CD70      | Hodgkin’s and diffuse large B-cell lymphomas Renal cell carcinoma Glioblastoma EBV+ undifferentiated nasopharyngeal sarcoma | Activated T and B-cells, dendritic cells TNF superfamily, cell associated ligand for CD27 CARs using CD27 result in “inherent costimulation” NCT00944905; NCT01015911 | | Herbst et al. (1996), Lens et al. (1999), Agathangelou et al. (1995), Junker et al. (2005), Law et al. (2006), Wischhusen et al. (2002), Chahlavi et al. (2005), Shaffer et al. (2006) |
| CD33      | AML, MDS APL CML JMML ALL (18%) | Myeloblasts, promyelocytes, myelocytes, monocytes, dendritic cells, macrophages Gemtuzumab ozogamicin removed from market in 2010 AAML03P1-2 doses in 350 children with AML comparable toxicity, response AAML0531 – Phase III in frontline AML therapy, results pending | | Cooper et al. (2011), Andrews et al. (1983), Matutes et al. (1985), Lucio et al. (2001) |
| CD47      | Pre-B ALL T cell ALL AML | Highly expressed in brain (requires therapeutic that is excluded from CSF) | Downregulates innate immune responses via engagement of SIRPα on phagocytes Independent poor prognostic factor in ALL and AML | Chao et al. (2011), Majeti et al. (2009) |
| IL7 Receptor α | Pre-B ALL, B-cell lymphomas 15% T-ALL | B-cell progenitors, T cell progenitors, nearly all mature T cells, some dendritic cells Mutated IL7Rα serves as oncogene in 10% of T-ALL and more rarely in Pre-B ALL | | Shochat et al. (2011) |
| Protein | Tumor Types | Functions | References |
|---------|-------------|-----------|------------|
| TSLPR  | Pre-B ALL (7%) | T cell progenitors, dendritic cells | Mutated TSLPR serves as oncogene in high-risk and Down's syndrome associated Pre-B ALL. TSLPR overexpression found in several groups of high-risk Pre-B ALL. Associated with t(X;14) or t(Y;14) and activates Jak2. ADVL1011 Phase I study of Jak inhibitor. | Russell et al. (2009), Harvey et al. (2010) |
|        | Pre-B ALL in Down's syndrome (60%) | | |
| ROR1   | 10% pre-B ALL (associated with t11;19) | Hematogones, Adipose and pancreas (low-level) | | Hudecek et al. (2010), Broome et al. (2011) |
| GD2    | Neuroblastoma | GD2(+) neuronal tissue (incl. peripheral sensory nerve fibers) | Functions to maintain and repair nervous tissue. Pain is a side effect in GD2-based antibody therapy. A number of clinical trials are active. | Ohmi et al. (2011), Kushner et al. (2011), Svennerholm et al. (1994) |
|        | Osteosarcoma | | |
|        | Soft-tissue sarcoma | Melanocytes | | |
|        | Melanoma | | |
|        | GLI2 | Diffuse intrinsic pontine glioma | CAR-based therapy and an Il-13-linked toxin therapy for glioma. Antibody-based therapy for Crohn's disease. | Hecker et al. (2010), Kawakami et al. (2006), Takenouchi et al. (2011), Kasaian et al. (2011) |
|        | Various carcinomas, including mesothelioma | Inducible on keratinocytes, lung epithelium, fibroblasts, smooth muscle | | |
| VEGFR2 | Tumor vasculature | Normal endothelium, CD4+FoxP3+ Treg cells | CAR-based trials (NCT01218867) and antibody-based trials with ramucirumab are open (NCT00917384). DVT was the initial toxicity in antibody-based trials. | Suzuki et al. (2010), Chinnasamy et al. (2010), Spratlin et al. (2010) |
| HER2   | Osteosarcoma | Low-level expression on lung parenchyma and high cell dose led to a severe adverse event in an adult CAR trial. Phase II antibody-based trial for osteosarcoma is completed (NCT00023998). CAR trial enrolling Her2-expressing advanced sarcomas (NCT00902044). | | Ahmed et al. (2009), Morgan et al. (2010) |
|        | Colon cancer | | |
|        | Breast cancer | | |
| ALK    | Neuroblastoma | Expressed on rare cells in CNS | Must be full-length to be a target for antibody or CAR therapy (as opposed to a fusion protein). | Webb et al. (2009) |
|        | Neuroectodermal tumors | | |
|        | Glioblastoma | | |
|        | Rhabdomyosarcoma | | |
|        | Melanoma | | |
| EGFRvIII | Gioma | None | Expression is tumor restricted. | Bax et al. (2009), Heimberger et al. (2006) |
| FGFR4  | Rhabdomyosarcoma | Expressed during myogenesis | | Taylor et al. (2009) |
| B7-H3  | Neuroblastoma | Mature dendritic cells | CAR and antibody reagents have been described. | Modak et al. (2001), Bumbaca et al. (2011) |
|        | Carcinoma cell lines | | |
| Glypican-3, 5 | Wilm's tumor | Rare in mature tissues | | Nakatsura et al. (2004), Saikali and Sinnett (2000), Thway et al. (2011) |
|        | Neuroblastoma | | |
|        | Rhabdomyosarcoma | | |
|        | Rhabdomyosarcoma | | |
|        | Hepatic carcinomas | | |
|        | Melanoma | | |
| FOLR1  | Rhabdomyosarcoma (alpha-folate receptor) | Luminal cell membrane of some epithelial tissues (and therefore may be hidden from direct recognition in intact tissues) | Antibody, farletuzumab, is currently being tested in ovarian and lung cancer (NCT00738699, NCT01218516). | Clifton et al. (2011) |
|        | Osteosarcoma | | |
|        | Carcinomas | | |
CD20
Rituximab (Rituxan®), an anti-CD20 monoclonal antibody, was the first approved for use in human cancer and remains one of the most successful immunotherapeutics in cancer therapy. Rituximab is now integrated into standard therapies for B-cell lymphomas (Coiffier et al., 2002; Thomas et al., 2006; Meinhardt et al., 2010; Kumar et al., 2011), chronic lymphocytic leukemia (Woyach et al., 2011), post-transplant lymphoproliferative disorder (Evens et al., 2010), and various autoimmune diseases (Stasi et al., 2001; Leah, 2011). Despite substantial depletion of normal B-cells following rituximab therapy, immunosuppression has not limited its use and B-cell numbers return to baseline within 3–6 months of completion of therapy (Thomas et al., 2006; Griffin et al., 2009). Not surprisingly, a variety of anti-CD20 based radioconjugates (Zinzani et al., 2008; Witzig et al., 2011) and CARs have also been successfully developed for adult malignancies (Till et al., 2008). In pediatric B-cell malignancies however, anti-CD20 therapies have had a limited role since neither ALL nor pediatric B-cell lymphomas commonly express CD20. (Jeha et al., 2006; Piccaluga et al., 2010) Interestingly though, recent data suggests that CD20 may be upregulated on ALL blasts after induction chemotherapy or with steroids, providing rationale for renewed efforts at the immunotherapeutic targeting of CD20 in pediatric ALL (Gaipa et al., 2005; Dworzak et al., 2008; NCT01363128; and NCT01279707).

CD52
Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 approved for use in adults with chronic lymphocytic leukemia. CD52 is expressed on essentially all T cell ALL blasts and the vast majority of B-cell ALL cases also show high-level CD52 expression (Piccaluga et al., 2010). Despite this, alemtuzumab as a single agent has limited activity in patients with refractory pediatric ALL (Angiolillo et al., 2009). Furthermore, CD52 is widely expressed throughout the hematopoietic system, including B-cells, T cells, NK cells, monocytes, macrophages, dendritic cells (DC), neutrophils, and mast cells. As a result, treatment with alemtuzumab is myelosuppressive and immunosuppressive (Tang et al., 1996), which limits enthusiasm for combining it with other therapies. Nevertheless, trials are underway to explore the efficacy of adding alemtuzumab to intensification or clofarabine on ALL blasts after induction chemotherapy or with steroids, providing rationale for renewed efforts at the immunotherapeutic targeting of CD20 in pediatric ALL (Gaipa et al., 2005; Dworzak et al., 2008; NCT01363128; and NCT01279707).

CD30
Alemtuzumab (Campath®) is a humanized monoclonal antibody to CD52 approved for use in adults with chronic lymphocytic leukemia. CD52 is expressed on essentially all T cell ALL blasts and the vast majority of B-cell ALL cases also show high-level CD52 expression (Piccaluga et al., 2010). Despite this, alemtuzumab as a single agent has limited activity in patients with refractory pediatric ALL (Angiolillo et al., 2009). Furthermore, CD52 is widely expressed throughout the hematopoietic system, including B-cells, T cells, NK cells, monocytes, macrophages, dendritic cells (DC), neutrophils, and mast cells. As a result, treatment with alemtuzumab is myelosuppressive and immunosuppressive (Tang et al., 1996), which limits enthusiasm for combining it with other therapies. Nevertheless, trials are underway to explore the efficacy of adding alemtuzumab to intensification or clofarabine on ALL blasts after induction chemotherapy or with steroids, providing rationale for renewed efforts at the immunotherapeutic targeting of CD20 in pediatric ALL (Gaipa et al., 2005; Dworzak et al., 2008; NCT01363128; and NCT01279707).

CANDIDATE CELL SURFACE IMMUNE TARGETS EXPRESSED ON SOLID TUMORS OF CHILDHOOD

GANGLIOSIDES
GD2’s precise role in cell biology remains unclear, but it appears to represent a developmental antigen, since it is expressed on mesenchymal stem cells derived from bone marrow, adipose, and umbilical cord blood (jin et al., 2006). The GD2 ganglioside is overexpressed on neuroblastoma, melanoma, and some sarcomas (Schulz et al., 1984; Navid et al., 2010) and recent, definitive studies demonstrated that anti-GD2 antibody therapy improves survival in high-risk neuroblastoma (Yu et al., 2010). GD2 on neuroblastoma has also been targeted in clinical trials using first generation CARs with some evidence for clinical activity (Park et al., 2007; Pule et al., 2008) and persistence (Louis et al., 2011). More recent preclinical studies demonstrated improved efficacy of GD2–CARs with the addition of chemokine receptors that improve homing to tumor (Craddock et al., 2010). In both monoclonal antibody and anti-GD2 CAR trials, targeting GD2 has been deemed safe.

Other gangliosides also represent attractive immune targets in pediatric oncology. GD3 is a disialoganglioside that is not expressed on normal tissues, but can be found on the surface of melanoma, soft-tissue sarcoma, and tumors of neuroectodermal origin (Hamilton et al., 1993). High tumor growth rates correlate with high-levels of GD3 synthesis (Ravindranath et al., 2007). First and second generation anti-GD3 CARs induce anti-tumor effects in animal models of melanoma (Lo et al., 2010). Finally, N-glycolylated gangliosides incorporate N-glycoloy, a molecule not produced by human cells but thought to be derived from diet, then incorporated into the tumor cell surface as a result of a response to hypoxia (Scursoni et al., 2010; Bernstein, 2011). N-glycoloy-GM3 was recently described to be present on the surface of Wilms’ tumor, neuroblastoma, and Ewing sarcoma (Mulens et al., 2010). Since N-glycoloy gangliosides are not expressed by any normal tissue, these molecules may provide an ideal target for toxin and/or CAR-based immunotherapies.

GROWTH FACTOR RECEPTORS AND ONCOGENES

IL-13Rα2
IL-13 is a Th2 cytokine that can bind to the low affinity IL-13Rα1 receptor, that signals in conjunction with IL-4Rα, or a high-affinity IL-13Rα2 receptor that binds and internalizes the
VEGFR2-derived peptides that could inhibit tumor angiogenesis

VEGFR2 (Flk-1/KDR), a transmembrane tyrosine kinase, is the epidermal growth factor receptor 2 (ERBB2) oncogene with a fatal adverse event (Morgan et al., 2010), likely related to a cytokine on its own (Wynn, 2003). The low affinity receptor complex activates Jak–STAT pathways of signal transduction while the high-affinity receptor, the normal expression of which is limited to lung epithelial cells and fibroblasts at low-levels that increase with injury (Kawakami et al., 2006; Hecker et al., 2010), signals through the AP-1 transcription factor and induces production of TGFβ (Fichtner-Feigl et al., 2006). A wide array of tumors express IL-13Ra2, including 80% of glioblastomas, most diffuse intrinsic pontine gliomas as well as melanoma and renal cell, prostate, ovarian, and pancreatic carcinomas (Kioi et al., 2008; Takenouchi et al., 2011). Preferential expression on tumor cells has led to targeting by a variety of immunotherapeutics, including a fusion protein between IL-13 and pseudomonas exotoxin (cintredakin besudotox), which failed to show enhanced efficacy compared to a standard therapy when regionally delivered in glioblastoma multiforme (Kioi et al., 2008; Kunwar et al., 2010), but studies are continuing in pediatric diffuse intrinsic pontine glioma (NCT0088006). Jensen and colleagues reported antitumor effects in a glioblastoma xenograft model of CAR transduced T cells using an affinity enhanced IL-13 instead of antibody-based motifs to direct T cell targeting (Oshima et al., 2000; Kahlon et al., 2004).

VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2

VEGFR2 (Flk-1/KDR), a transmembrane tyrosine kinase, is the primary cellular receptor for vascular endothelial growth factor receptor (VEGF). VEGFR2 is unique among tumor targets since it is expressed on tumor vasculature instead of the tumor itself, as well as on regulatory T cells (Brown et al., 1993). Mouse models of malignancy originally identified CD8+ T cell clones specific for VEGFR2-derived peptides that could inhibit tumor angiogenesis and growth (Dong et al., 2006; Suzuki et al., 2010). VEGFR2-specific CARs have demonstrated antitumor activity in murine models (Chinnasamy et al., 2010) and a clinical trial is currently underway (NCT01218867). While the potential for targeting both T regulatory cells and tumor vasculature is compelling, caution in immune based targeting of VEGFR2 should be exercised as it is expressed at lower levels on normal blood vessels and other tissues and is upregulated on blood vessels during wound healing (Chinnasamy et al., 2010; Edelbauer et al., 2010). In addition, elimination of T regulatory cells may lead to autoimmunity.

HER2/Neu (ERBB2)

Monoclonal antibody-based targeting of the amplified human epidermal growth factor receptor 2 (HER2/Neu) oncogene with trastuzumab (Herceptin®), in breast cancer has been a major success of tumor immunotherapy (Gonzalez-Angulo et al., 2006). Although not clearly credentialed as an oncogene in pediatric cancers (Gilbertson, 2005), Her2/Neu is expressed on Wilms’ tumor, medulloblastoma, and osteosarcoma but at levels that are not sufficient for antitumor effects using trastuzumab (Ragab et al., 2010). However, investigators have demonstrated activity of anti-Her2/Neu CARs created using the trastuzumab binding motif (Ahmed et al., 2009; Zhao et al., 2009). Thus the threshold of expression required for targeting cells with CARs may be lower than that for monoclonal antibodies. Unfortunately, the first clinical trial of an anti-Her2/Neu CAR in adult cancer was associated with a fatal adverse event (Morgan et al., 2010), likely related to a combination of high T cell dose and low-level Her2/Neu expression in the lung, which resulted in massive cytokine release. This event does not necessarily preclude future immune targeting of ERBB2, as lower cell doses or different combinations of signaling motifs may ultimately prove to be safe. In fact, a phase I trial of anti-Her2/Neu CAR therapy in osteosarcoma using a cautious dose escalation scheme is currently underway and substantial toxicity has not been observed so far (NCT00902044).

ANAPLASTIC LYMPHOMA KINASE

Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was first discovered as a partner with nucleophosmin in the oncogenic fusion protein found in ALCLs (Webb et al., 2009). During neuronal development, ALK is expressed as a transmembrane protein, then downregulated soon after birth. In mature animals, ALK shows restricted CNS expression, limited to rare neurons, pericytes, and endothelial cells (Pulford et al., 1997; Falini et al., 1999). The true ligand for ALK is still in question as some studies implicate pleiotrophin/midkine, while others do not (Moog-Lutz et al., 2005; Wellstein and Toretzky, 2011). In either case, a double knockdown of ALK and pleiotrophin blocks glioma tumorigenesis. (Grzelinski et al., 2009) Full-length, cell surface ALK expression is observed in a wide array of tumors including lung cancer, neuroblastoma, neuroectodermal tumors, glioblastoma, rhabdomyosarcoma, and melanoma (Webb et al., 2009) and recently ALK was identified as an oncoprotein in both familial and sporadic neuroblastoma (George et al., 2008; Mosse et al., 2008). Thus, ALK represents a promising target for both oncogene-inhibition and immunotherapy.

EGFRvIII

A mutant, constitutively activated form of the epidermal growth factor receptor, EGFRvIII, is overexpressed on the surface of approximately 20% of adult and pediatric gliomas (Heimberger et al., 2005; Bax et al., 2009). EGFRvIII has been targeted with T cell based immunotherapy as a vaccine (Sampson et al., 2010), and in addition, CAR vectors targeting EGFRvIII have been produced and validated in vitro, and clinical trials are awaited (Bullain et al., 2009; Ohno et al., 2010). Like ALK, the potential role of EGFRvIII in the growth/survival of these tumors makes it a promising target for both oncogene-inhibition and immunotherapy.

FIBROBLAST GROWTH FACTOR RECEPTOR 4

There are over 20 known fibroblast growth factors, the activity of which are mediated by four distinct receptors. Fibroblast growth factors play myriad roles in cell signaling, growth and differentiation, and mutations or alterations in this system have been described in a number of malignancies (Olsen et al., 2003; Weishe et al., 2011). Antibodies to fibroblast growth factor receptor 3 (FGFR3) are currently undergoing trials in multiple myeloma (NCT00866138). FGFR4 is a new target identified in pediatric solid tumors that is overexpressed by nearly all rhabdomyosarcomas with activating point-mutations observed in more aggressive disease (Taylor et al., 2009; Paulson et al., 2011) and with limited expression on normal myocytes. Thus, it also serves as a candidate target for both oncogene-inhibition and immunotherapy.
OTHER CELL SURFACE MOLECULES

4IgB7-H3

Most adhesion receptors are broadly expressed, but some such as B7-H3 are expressed in a more restricted fashion, and thus offer the potential for immune targeting in cancer. B7-H3 has two isoforms; the 2Ig-B7-H3 isoform is expressed on mature DC and a number of carcinoma cell lines (Zhang et al., 2005) but has not been reported on pediatric tumors. However, the 4Ig-B7-H3 isoform is expressed on neuroblastoma (Castriconi et al., 2004) and has been reported to be the target of 8H9 (Xu et al., 2009), a monoclonal antibody which binds to a wide array of pediatric tumors, including sarcomas and most brain tumors (Modak et al., 2001, 2002). Masking of 4Ig-B7-H3 enhances NK cell lysis of neuroblastoma cell lines, suggesting that it may negatively regulate NK signaling (Castriconi et al., 2004). Clinical studies are currently underway using radioconjugated 8H9 for treatment of intraperitoneal desmoplastic small round cell tumor (NCT01099644) as well as for leptomeningeal spread of 8H9 binding tumors (NCT00089245). Due to concerns regarding hepatic expression of the 8H9 binding antigen, systemic administration of this monoclonal antibody has not been pursued. It remains unclear whether hepatic expression of 4IgB7-H3 will preclude systemic targeting of this antigen.

GLYPICANS

Glypican-3 is a cell surface peptidoglycan found on the surface of hepatocellular carcinoma and melanoma, and glypican-3 mRNA has been demonstrated on embryonal tumors including neuroblastoma and Wilms’ tumor (Saikali and Sinnett, 2000; Nakatsura et al., 2004). Recently, a homologous molecule, glypican-5 was demonstrated to be amplified in rhabdomyosarcoma and to play a role in growth/survival of this tumor (Williamson et al., 2007). Thus, at least two glypican family of molecules represent potential targets in embryonal tumors.

ALPHA-FOLATE RECEPTOR

A humanized antibody specific for alpha-folate receptor (FOLR1), farletuzumab, is currently in clinical trials for patients with ovarian carcinoma (Konner et al., 2010). The expression of this transmembrane folate receptor in normal tissues is limited to the luminal side of epithelium and therefore is not accessible to the vascular system and would not be targeted by monoclonal antibody therapies (Garin-Chesa et al., 1993; Ross et al., 1994). Analyses contained within the public tissue expression database1 document overex-

Table 2 | Non-CTA, MHC restricted immune targets expressed in pediatric cancer.

| Class/target | Expression | Notes | References |
|--------------|------------|-------|------------|
| **DIFFERENTIATION ANTIGENS** | | | |
| Proteinase-3 (PR-3) | AML (M2, M3 > M4 > M1) | PR-1 is a PR-3 derived peptide that has elicited immune responses in clinical trials | Dengler et al. (1995), Moidlrem et al. (1996), Rezvan (2008) |
| Hyaluronic acid-mediated motility (RHAMM, CD168) | ≈70% AML | Limited data on pediatric versus adult leukemias | Greiner et al. (2002, 2003) |
| STEAP (six-transmembrane epithelial antigen of prostate) | Ewing sarcoma | Data too limited to denote approximate percentage | Hu-Lieskovan et al. (2005), Hubert et al. (1999) |
| **ONCOGENES** | | | |
| Flt3–ITD | ≈25% Pediatric AML | HLA-A1 epitope identified | Brown et al. (2004) |
| Her2/Neu | ≈60% Osteosarcoma* | HLA-A1, A24, DR5, DR4 epitopes identified | Gilbertson (2005), Ahmed et al. (2009), Gorlick et al. (1999), Hughes et al. (2004), Ahmed et al. (2007), Tong et al. (2004) |
| WT1 | ≈70–80% AML | HLA-A2, B8, DR4, DR9 epitopes identified | Inoue et al. (1997), Rosenfeld et al. (2003), Ohta et al. (2009), Nakatsuka et al. (2006) |
|Survivin | All tumors | Fratricide reported by high-affinity survivin-specific CTLs due to T cell survivin expression | Leisegang et al. (2010), Coughlin et al. (2004, 2006), Rapport et al. (2011) |
|Telomerase (hTERT) | All tumors | HLA-A2, B8, DR4, DR9 epitopes identified | Rapport et al. (2011) |
|BCR–ABL (p210) | ≈90% Alveolar rhabdomyosarcoma | HLA-B7 epitope identified | van den Broeke et al. (2006) |
|PAX3–FKHR | ≈90% Alveolar rhabdomyosarcoma | HLA-B7 epitope identified | Worley et al. (2001) |
|SYT–SSX1, SSX2 | 100% Synovial sarcoma | HLA-B7, DR11 epitope identified | Yotnda et al. (1998a) |
|ETV6–AML1 | ≈25% ALL | HLA-B7, DR11 epitope identified | Yotnda et al. (1998b) |
|PML–RARα | 100% M3-AML | HLA-B7, DR11 epitope identified | Gambacorti-Passerini et al. (1993) |

*Expression in osteosarcoma is not associated with amplification as observed in Her2/Neu expressing breast carcinomas.
pression in some pediatric tumors as well, including osteosarcoma and Ewing’s sarcoma. CAR-based cell therapies targeting FOLR1 are underway and could potentially be extended to FOLR1 pediatric tumors (Kershaw et al., 2006).

**MHC RESTRICTED IMMUNE TARGETS IN PEDIATRIC CANCER: WILMS’ TUMOR ANTIGEN**

Wilms’ tumor antigen (WT1) is expressed by several pediatric tumors, and appears to be immunogenic (Cheever et al., 2009). Some concerns remain regarding expression on hematopoietic stem cells, renal podocytes, and potentially other cycling populations, but the community remains optimistic that WT1 may prove to be an effective tumor antigen, as it was ranked the most promising of all tumor antigens by the NCI (Cheever et al., 2009). Several small, non-randomized studies have demonstrated WT1 specific immunity following peptide based vaccination and in some cases this was associated with evidence for anti-leukemic activity. An ongoing vaccine trial is underway for patients with recurrent leukemias and lymphoma at the NCI Pediatric Oncology Branch (NCT00923910).

**SURVIVIN**

Survivin is an anti-apoptotic molecule that is overexpressed in most tumors, but also has widespread low-level expression in normal tissues. Survivin-specific T cells have been isolated from patients with cancer, including neuroblastoma, and some groups have demonstrated that survivin-specific T cells can mediate tumor lysis (Cheever et al., 2009). Based upon these results, several investigators sought to develop high-affinity survivin-specific T cells. Remarkably, such cells are able to lyse nearly all tumors but also mediate fratricide of normal T cells due to survivin expression following activation (Leisegang et al., 2010). Thus, normal tissue expression of survivin appears likely to limit the effectiveness of immunotherapies targeting this antigen and similar limitations could apply to other broadly expressed tumor antigens.

Several other non-cancer testis antigens that are candidate MHC restricted T cell targets expressed in pediatric tumors are shown in Table 2.

**CANCER–TESTIS ANTIGENS**

Cancer testis antigens [also referred to as cancer germline genes (CGG)] are expressed in a wide array of cancers, with normal tissue expression limited to testicular germ cells and placental trophoblasts (see detailed reviews Fratta et al., 2011 and detailed listing of the genes at http://www.cta.lncc.br). The first tumor antigen identified, MAGE-A1, is a prototype and since its discovery the family has expanded to comprise 70 families with over 140 antigens. Over half of the CTAs are encoded by the X chromosome (X-CTA) and it is estimated that approximately 10% of the X chromosome encodes for these molecules. Expression is regulated in large part by epigenetic factors, although the BORIS transcription factor has also been shown to be a potent inducer of their expression (Fratta et al., 2011). The biologic function of CTAs has remained elusive and their scientific interest has been primarily based upon their inherent immunogenicity and their restricted tissue expression, which has made them compelling immune targets.

The CTA family officially encompasses a vast number of molecules (Almeida et al., 2009), but a much smaller number have been demonstrated to be immunogenic and thus are truly promising targets for immunotherapies (detailed in http://www.cancerimmunity.org/peptidedatabase/tumorspecific.htm). Furthermore, analysis of CTAs in pediatric tumors has been limited (Liu et al., 2000; Zendman et al., 2002; Foell et al., 2008; Jacobs et al., 2008; Oba-Shinjo et al., 2008; Grau et al., 2009; Pollack et al., 2011). A summary of the studies reporting CTAs in pediatric tumors is shown in Table 3, but several caveats should be emphasized. First, most studies involve limited numbers of tumors, which are not adequate to reliably define the percent of tumors of any specific histology expressing CTAs, and most studies have not been confirmed. Thus, the prevalence of expression listed for any histology must be considered an approximation at best.

Second, whereas NY-ESO-1 and PRAME each represent one gene, the rest of the CTAs shown in Table 3 represent gene families, for which expression is likely to vary across the specific genes.
within that family. For example, within the MAGE A family at least eight different immunogenic genes have been identified (A1-4, 6, 9, 10, and 12). Given that targeted immunotherapy trials typically focus on one antigen, the percent of tumors that could be targeted with any given vaccine will be limited to those tumors expressing that specific gene. Third, very few studies have incorporated immunohistochemistry or other approaches to confirm protein expression of CTAs in pediatric tumors. In the few that have, some have reported that mRNA expression correlated with protein expression (Jacobs et al., 2007), while others have noted that mRNA positivity is associated with patchy or very weak immunohistochemical staining (Oba-Shinjo et al., 2008). Together, one can conclude that CTAs are likely to be expressed in a sizable percentage of childhood cancers, but substantially more work is needed to accurately define the prevalence of CTA protein expression among pediatric histologies, to better characterize the intensity, distribution, and extent of homogeneity of CTA expression within tumors. Clarification of these issues is needed before one can accurately predict whether targeting CTAs for immunotherapy of pediatric cancer is likely to be effective.

One tumor where robust CTA protein expression has been clearly documented is synovial sarcoma. NY-ESO-1 expression is seen in approximately 70% of synovial sarcomas and is characterized by diffuse, intense protein expression. Furthermore, preliminary results demonstrate that meaningful antitumor effects can result from targeting NY-ESO-1 in these tumors, most recently using adoptive transfer of T cells genetically engineered to express a high-affinity NY-ESO-1 peptide specific T cell receptor (Robbins et al., 2011). Despite these exciting results, challenges in translating this therapy on a larger scale epitomize the challenges unique to T cell based immunotherapies. The TCR used in this therapy targets an HLA-A2 restricted peptide, and approximately 40% of the Caucasian population expresses HLA-A2, while lesser percentages are found in individuals of Asian and African descent. There are approximately 800 new diagnoses of synovial sarcoma each year, of which approximately 200 small tumors (<5 cm) have an excellent prognosis with surgery alone2. Thus, fewer than 200 new cases of synovial sarcoma per year could benefit from this exciting emerging therapy. Given the rarity of this disease, it is easy to understand why executing trials and standardizing MHC restricted T cell based therapies for rare cancers is challenging.

FERTILE GROUND FOR NEW CANCER IMMUNOTHERAPEUTICS

We have discussed the major, current attractive targets for immunotherapy in pediatric cancer taking into consideration expression on normal or vital tissues. While much progress has been made in pediatric oncology, some subgroups, such as those with metastatic sarcomas and brain tumors, have not seen major improvement in survival over the past few decades despite intensifying chemotherapies. The long-term benefit of monoclonal antibody therapy has yet to be proven and none except anti-GD2 have become standard therapy in pediatric oncology. In addition to further developing monoclonal antibody therapy, the field is moving to use the target cell specificity of antibody or antibody-like molecules as a means to deliver toxins or immune effector cells to the tumor. Advances in small molecule technology, production of new forms of antibody, and innovations in cell production techniques are responsible for recent exciting results, albeit in small numbers of patients, mostly limited to adult oncology. Still, these techniques are just now becoming applicable to the clinic and are likely to be a fertile arena for clinical progress in pediatric oncology for the next decade.

REFERENCES

Agathanggelou, A., Niedobitek, G., Chen, R., Nicholls, J., Yin, W., and Young, L. S. (1995). Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma. Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells. Am. J. Pathol. 147, 1152–1160.

Ahmed, N., Ratnayake, M., Savoldo, B., Perlaky, L., Dotti, G., Wels, W. S., Bhattacharjee, M. B., Gilbertson, R. J., Shine, H. D., Weiss, H. L., Rooney, C. M., Heslop, H. E., and Gottschalk, S. (2007). Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 67, 5957–5964.

Ahmed, N., Salsman, V. S., Yvon, E., Louis, C. U., Perlaky, L., Wels, W. S., Dishop, M. K., Kleinerman, E. E., Pule, M., Rooney, C. M., Heslop, H. E., and Gottschalk, S. (2009). Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol. Ther. 17, 1779–1787.

Almeida, L. G., Sakabe, N. J., deOliveira, A. R., Silva, M. C., Mundstein, A. S., Cohen, T., Chen, Y. T., Chua, R., Gurung, S., Gnjatic, S., Jungbluth, A. A., Caballero, O. L., Bairoch, A., Kiesel, E., White, S. L., Simpson, A. J., Old, L. I., Camargo, A. A., and Vasconcelos, A. T. (2009). CT database: a knowledge-base of high-throughput and curated data on cancer-testis antigens. Nucleic Acids Res. 37, D816–D819.

Andrews, R. G., Tokor-Storb, B., and Bernard, I. D. (1983). Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62, 124–132.

Angiolillo, A. L., Yu, A. L., Reaman, G., Ingle, A. M., Scocola, R., and Adamson, P. C. (2009). A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children’s Oncology Group report. Pediatr. Blood Cancer 53, 978–983.

Ansell, S. M., Horwitz, S. M., Engert, A., Khan, K. D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A., and Borchmann, P. (2007). Phase II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J. Clin. Oncol. 25, 2764–2769.

Ascierto, P. A., Simeone, E., Szol, M., Fu, Y. X., and Melero, I. (2010). Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 37, 508–516.

Baeuerle, P. A., and Reinhardt, C. (2009). Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941–4944.

Bargou, R., Leo, E., Zugmaier, G., Klinger, M., Goebeler, M., Knoop, S., Nopprenay, R., Viardot, A., Hess, G., Schüler, M., Emsele, H., Brandl, C., Wolf, A., Kirchinger, P., Klappers, P., Schmidt, M., Riethmüller, G., Reinhardt, C., Baeuerle, P. A., and Kufer, P. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977.

Bax, D. A., Gaspar, N., Little, S. E., Marshall, L., Perryman, L., Regarai, M., Viana-Pereira, M., Vuononvirta, R., Sharp, S. Y., Reis-Filho, J. S., Stå vale, J. N., Al-Sarraj, S., Reis, R. M., Vassal, G., Pearson, A. D., Hargrave, D., Ellison, D. W., Workman, P., and Jones, C. (2009). EGFRVIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin. Cancer Res. 15, 5753–5761.

Bernstein, M. L. (2011). Targeted therapy in pediatric and adolescent oncology. Cancer 117, 2268–2274.

Boon, K., Edwards, J. B., Sui, I. M., Olschner, D., Eberhart, C. G., Marra, M. A., Straussberg, R. L., and Riggins, G. J. (2003). Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22, 7687–7694.
protein CD22 is controlled by a novel membrane proximal cytoplasmic motif. J. Biol. Chem. 273, 27869–27875.

Chao, M. P., Alizadeh, A. A., Tang, C., Jan, M., Weissman-Tsukamoto, R., Zhao, F., Park, C. Y., Weissman, I. L., and Majeti, R. (2011). Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71, 1374–1381.

Cheever, M. A., Allison, J. P., Ferris, A. S., Finn, O. J., Hastings, B. M., Hecht, T. T., Mellman, I., Prindiville, S. A., Viner, J. L., Weiner, L. M., and Matrisian, L. M. (2009). The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translation and research. Clin. Cancer Res. 15, 5322–5337.

Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shriml, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., and Rosenberg, S. A. (2010). Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngeneic tumors in mice. J. Clin. Invest. 120, 3952–3968.

Christoffersen, T., Guren, T. K., Spindler, K. L., Dahl, O., Lonn, P. E., and Gjertsen, B. T. (2009). Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. Eur. J. Pharmacol. 625, 6–22.

Clifton, G. T., Sears, A. K., Clive, K. S., Holmes, J. P., Mittendorf, E. A., Loanidies, C. G., Ponniah, S., and Peoples, G. E. (2011). Folate receptor alpha: a storied past and promising future in immunotherapy. Hum. Vaccin. 7, 183–190.

Coiffler, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., Reyes, F., Ledermann, P., and Gisselbrecht, C. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N. Engl. J. Med. 346, 235–242.

Cooper, T. M., Franklin, J., Gerbing, R. B., Alonzo, T. A., Hurwitz, C., Raimondi, S. C., Hirsch, B., Smith, F. O., Mathew, P., Arice, R. J., Feusner, J., Iannone, R., Lavey, R. S., Meshinchi, S., and Gamin, A. (2011). AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute lymphoblastic leukemia: a report from the children’s oncology group. Cancer.

Cortes, J., Hochhaus, A., Hughes, T., and Kantarjian, H. (2011). Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. J. Clin. Oncol. 29, 524–531.

Coughlin, C. M., Fleming, M. D., Carroll, R. G., Pawel, B. R., Hogarty, M. D., Shan, X., Vance, B. A., Cohen, J. N., Iaria, S., Lord, E. M., Wexler, M. H., Danet-Desnoyers, G. A., Pinkus, J. L., Pinkus, G. S., Maris, J. M., Grupp, S. A., and Vonderheide, R. H. (2006). Immunosurveillance and survival-specific T-cell immunity in children with high-risk neuroblastoma. J. Clin. Oncol. 24, 5725–5734.

Coughlin, C. M., Vance, B. A., Grupp, S. A., and Vonderheide, R. H. (2004). RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103, 2046–2054.

Crandall, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., and Foster, A. E. (2010). Enhanced tumor trafficking of CD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780–788.

Czerniecki, B. J., Koski, G. K., Koldovsky, U., Xu, S., Cohen, P. A., Mick, R., Nisenbaum, H., Pasha, T., Xu, M., Fox, K. R., Weinstein, S., Orel, S. G., Vonderheide, R., Coukos, G., DeMichele, A., Araujo, L., Spitz, F. R., Rosen, M., Levine, B. L., June, C., and Zhang, P. J. (2007). Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 67, 1842–1852.

Dengler, R., Munstermann, U., al-Batran, S., Hausner, I., Faderl, S., Nerl, C., and Emmerich, B. (1995). Immunocytochemical and flow cytometric detection of protease 3 (myeloblastin) in normal and leukemic myeloid cells. Br. J. Haematol. 89, 250–257.

Dhomen, N., and Marais, R. (2009). BRAF signaling and targeted therapies in melanoma. Hematol. Oncol. Clin. North Am. 23, 529–545, ix.

Diel, K. M., Keller, E. T., and Ignatowski, K. M. (2007). Why should we still care about oncogenes? Mol. Cancer Ther. 6, 418–427.

Dong, Y., Qian, J., Ibrahim, R., Berzofsky, J. A., and Khleif, S. N. (2006). Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. J. Immunother. 29, 32–40.

Dowzick, M. N., Schumich, A., Printz, D., Potscher, U., Husak, Z., Attarbaschi, A., Basso, G., Gaipa, G., Ratei, R., Mann, G., and Gadner, H. (2008). CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during treatment setting: the stage for anti-CD20 directed immunotherapy. Blood 112, 3982–3988.

Edelbauer, M., Datta, D., Vos, I. H., Basu, A., Stack, M. P., Reinders, M. E., Shou, M., Calcadilla, K., Gan, P., and Briscoe, D. M. (2010). Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo. Blood 116, 1980–1989.

Enns, A. M., Roy, K., Sterrenberg, D. W. M., Hell, M., de Groot, C., Housseau, F., and Gordon, L. I. (2010). Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr. Opin. Oncol. 22, 383–394.

Falini, B., Pullord, K., Pucciarini, A., Carbone, A., De Wolf-Peeters, C., Cordell, J., Fizzotti, M., Santucci, A., Pellici, P. G., Pileri, S., Campo, E., Ott, G., Delsol, G., and Mason, D. Y. (1999). Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 94, 3509–3515.

Fichtner-Feigl, S., Strober, W., Kawakami, K., Puri, R. K., and Kitani, A. (2006). IL-13 signaling through the IL-13Rα2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat. Med. 12, 99–106.

Flynn, J. M., and Byrd, J. C. (2000). Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. 12, 574–581.

Foell, J. L., Hesse, M., Volkmann, I., Schmiedel, B. J., Neumann, I., and Stagee, M. S. (2008). Membrane-associated phospholipase A2 beta (LPlp1) is an Ewing tumour-associated cancer/testis antigen. Pediatr. Blood Cancer 51, 228–234.

Forero-Torres, A., Leonard, J. P., Younes, A., Rosenblatt, J. D., Brice, P., Bartlett, N. L., Bosly, A., Pinter-Brown, L., Kennedy, D., Sievers, F. L., and Gopal, A. K. (2009). A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br. J. Haematol. 146, 171–179.

Fratta, E., Coral, S., Covre, A., Parisi, G., Colizzi, F., Danielli, R., Marie Nicolay, H. J., Sigalotti, L., and Maia, M. (2011). The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol. Oncol. 5, 164–182.

www.frontiersin.org January 2012 | Volume 2 | Article 3 | 11
HER-2/neu-positive breast cancer. Oncologist 11, 857–867.

Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsworth, G. P., Healey, J. H., and Meyers, P. A. (1999). Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. 17, 2781–2788.

Grau, E., Oltra, S., Martinez, F., Orellana, C., Cañete, A., Fernández, J. M., Fernández-Martí, M., and Castel, V. (2009). MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors. J. Cancer Res. Clin. Oncol. 135, 523–531.

Greiner, J., Ringhofer, M., Taniguchi, M., Hauser, T., Schmitt, A., Döhner, H., and Schmitt, M. (2003). Characterization of several leukemia-associated antigens induc- ing immunological immune responses in acute and chronic myeloid leukemia. Int. J. Cancer. 106, 224–231.

Greiner, J., Ringhofer, M., Taniguchi, M., Schmitt, A., Kirchner, D., Krähn, G., Heilmann, V., Gshwend, J., Bergmann, L., Döhner, H., and Schmitt, M. (2002). Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp. Hematol. 30, 1029–1035.

Griffin, T. C., Weitzman, S., Weinstein, H., Chang, M., Cairo, M., Hutchison, R., Shiramizu, B., Wiley, J., Woods, D., Barnich, M., Gross, T. G., and Children's Oncology Group. (2009). A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr. Blood Cancer. 55, 177–181.

Grzelinski, M., Steinberg, F., Martins, T., Czubayko, E., Lamszus, K., and Aigner, A. (2009). Enhanced anti-tumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia 11, 145–156.

Guadagni, S., Recker, K., Lawes, H. J., Dirksen, U., Tröger, A., Wieczorek, U., Furlan, S., Göbel, U., and Hanenberg, H. (2006). Identification of candidate target antigens for antibody-based immunotherapy in childhood B-cell precursor ALL. Klin. Padiatr. 218, 327–333.

Hamilton, W. B., Helling, F., Lloyd, K. O., and Livingston, P. O. (1993). Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int. J. Cancer 53, 566–573.

Harvey, R. C., Mullighan, C. G., Chen, I. M., Whaley, W., Mikhail, F. M., Carroll, A. J., Kang, H., Liu, W., Dobbin, K. K., Smith, M. A., Carroll, W. L., Devidas, M., Bow- man, W. P., Camitta, B. M., Rea- man, G. H., Hunger, S. P., Downing, J. R., and Willman, C. I. (2010). Rearrangement of CRLF2 is associ- ated with mutation of JAK kinases, alteration of IKZF1, hispanic/latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115, 5312–5321.

Hecker, M., Zasloná, Z., Kwapiszewska, G., Niess, G., Zakrezewicz, A., Her- genreiter, E., Wilhelm, J., Marsh, L. D., Gassling, D., Krepel, I., Lohmeyer, J., Dimmeler, S., Seeger, W., Weissmann, N., Schermuly, R. T., Kneidinger, N., Eckelberg, O., and Motty, R. E. (2010). Disregu- lation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 182, 805–818.

Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., and Aldape, K. (2005). Prognostic effect of epi- dermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 11, 1462–1466.

Herbst, R., Raff, T., and Stein, H. (1996). Phenotypic modulation of Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J. Pathol. 179, 54–59.

Herrera, L., Bostrom, B., Gore, L., Sandler, E., Lew, G., Schlegel, P. G., Aquino, V., Ghetie, V., Vitetta, E. S., and Schindler, J. (2009). A phase 1 study of Combotok in pediatric patients with refrac- tory B-lineage acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31, 936–941.

Hubert, R. S., Vivano, I., Chen, E., Rastegar, S., Leong, K., Mitchell, S. C., Madraswala, R., Zhou, Y., Kuo, J., Raitano, A. B., Jakobovits, A., Saf- man, D. C., and Alar, D. E. (1999). STEAP: a prostate-specific-cell surface antigen highly expressed in human prostate tumors. Proc. Natl. Acad. Sci. U.S.A. 96, 14523–14528.

Hudecek, M., Schmitt, T. M., Baskar, S., Lupo-Stanghellini, M. T., Nishida, Y., Yamamoto, T. N., Bleakley, M., Turtle, C. J., Chang, W. G., Greis- man, H. A., Wood, B., Maloney, D. G., Jensen, M. C., Rader, C., and Riddell, S. R. (2010). The B-cell tumor-associated antigen ROR1 can be targeted with T cells mod- ified to express a ROR1-specific chimeric antigen receptor. Blood 116, 4532–4541.

Hughes, D. P., Thomas, D. G., Giordano, T. J., Baker, L. H., and McDonagh, K. T. (2004). Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 64, 2047–2053.

Hu-Lieskovsky, S., Zhang, J., Wu, L., Shimada, H., Schofield, D. E., and Triche, T. J. (2005). EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed pheno- type of Ewing's family of tumors. Cancer Res. 65, 4633–4644.

Inoue, K., Ogawa, H., Sonoda, Y., Kikuchi, Y., Hama, C., and Oka, H., Miyake, S., Tamaki, H., Oji, Y., Yamagami, T., Tatekawa, T., Soma, T., Kishimoto, T., and Sugiyama, H. (1997). Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 89, 1405–1412.

Jacobs, J. F., Brasseur, F., Hulsbergen-van de Kaa, C. A., van de Rakt, M. W., Figdor, C. G., Adema, G. J., Hoogero- brugge, P. M., Coule, P. G., and de Vries, J. I. (2007). Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int. J. Cancer 120, 67–74.

Jacobs, J. F., Grauer, O. M., Brasseur, F., Hoogeroo- brugge, P. M., Wesseling, P., Gidding, C. E., van de Rakt, M. W., Figdor, C. G., Coule, P. G., de Vries, I. J., and Adema, G. I. (2008). Selective-cancer-germline gene expression in pediatric brain tumors. J. Neurooncology. 88, 273–280.

James, S. E., Greenberg, P. D., Jensen, M. C., Lin, Y., Wang, J., TILL, B. G., RautitischeK, A. A., Forman, S. J., and Press, O. W. (2008). Antigen sensitiv- ity of CD22-specific chimeric TCR is modulated by target epitope dis- tance from the cell membrane. J. Immunol. 180, 7028–7038.

Jeha, S., Behm, F., Pei, D., Sandlund, J. T., Ribeiro, R. C., Razzouk, B. I., Rubnitz, J. E., Hiayua, N., Howard, S. C., Cheng, C., and Pai, C. H., (2006). Prognostic significan- ce of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 108, 3302–3304.

Jin, H. I., Nam, H. Y., Bae, Y. K., Kim, S. Y., Im, I., Oh, W., Yang, Y. S., Choi, S. J., and Kim, S. W. (2006). GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mes- enchymal stem cells. Cell. Mol. Life Sci. 67, 1845–1858.
Jungbluth, A. A., Antonescu, C. R., Busam, K. J., Iversen, K., Kolb, D., Coplan, K., Chen, Y. T., Stockert, E., Ladanyi, M., and Old, L. J. (2001). Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int. J. Cancer 94, 252–256.

Junker, K., Hindermann, W., von Eggeling, F., Diegmann, J., Haessler, K., and Schubert, J. (2005). CD70: a new tumor specific biomarker for renal cell carcinoma. J. Urol. 173, 2150–2153.

Kahlon, K. S., Brown, C., Cooper, L. J., Rautbiesch, A., Forman, S. J., and Jensen, M. C. (2004). Specific recognition and killing of glioblastoma multiforme by interventional γ-3-7-2-7 redirected cytolytic T cells. Cancer Res. 64, 9160–9166.

Kalo, M., Levine, B. L., Porter, D. L., Katz, S., Krupp, S. A., Bagg, A., and June, C. H. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95r73.

Kasaian, M. T., Raible, D., Marquette, Kalos, M., Levine, B. L., Porter, D. L., Kahlon, K. S., Brown, C., Cooper, Yang, J. C., Rosenberg, S. A., and Tchistiakova, L. (2011). IL-2 and IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger receptor activity of IL-13Ralpha2. J. Immunol. 187, 561–569.

Kavalla, C., Nakahara, Y., Ueda, S., Hawkins, C., Taylor, M. D., Smith, C. A., and Rutka, J. T. (2008). Expression of MAGE and GaGc genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J. Neurosurg. Pediatr. 1, 305–313.

Kawamura, K., Terabe, M., Kawakami, M., Berzofsky, J. A., and Puri, R. K. (2006). Characterization of a novel human tumor antigen inter leukin-13 receptor alpha2 chain. Cancer Res. 66, 4434–4442.

Kennedy, M. K., Willis, C. R., and Armitage, R. J. (2006). Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118, 143–152.

Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., Chen, C. C., Yang, J. C., Rosenberg, S. A., and Hwu, P. (2006). A phase I Study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115.

Koiv, M., Seetharam, S., and Puri, R. K. (2008). Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol. Cancer Ther. 7, 1579–1587.

Kochenderfer, J. N., Wilson, W. H., Janik, I. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Marie, L., Raffeld, M., Nathan, D. A., Lanier, B. J., Morgan, R. A., and Rosenberg, S. A. (2010). Eradication of B lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099–4102.

Konner, J. A., Bell-McGuinn, K. M., Sabatini, P., Hensley, M. L., Tew, W. P., Ryan, M. C., Smith, L., Simon, R., Ryan, U., Kunwar, S., Chang, S., Westphal, M., Berzofsky, J. A., and Puri, R. K. (2011). Rituximab in combination with multi agent chemotherapy for pediatric follicular lymphoma. Pediatr. Blood Cancer 57, 317–320.

Kuwars, S., Chang, S., Westphal, M., Vogelbaum, M., Sampson, J., Barnett, G., Shaffrey, M., Ram, Z., Piepermeier, J., Prados, M., Croteau, D., Pedain, C., Leland, P., Husain, S. B., Joshi, B. H., Puri, R. K., and PRE-CISE Study Group. (2010). Phase III randomized trial of CED of IL13-PE38QQR vs. Gladed wafers for recurrent glioblastoma. Neurooncology 12, 871–881.

Kushner, B. H., Kramer, K., Modak, S., Gerald, W., and Cheung, N. K. (2011). Antitumor activity of chimeric sFc-DV28(T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16, 2769–2780.

Liu, X., Helman, L. J., Yeung, C., Bera, T. K., Lee, B., and Pastan, I. (2000). XAGE-1, a new gene that is frequently expressed in Ewing’s sarcoma. Cancer Res. 60, 4752–4755.

Lo, A. S., Ma, Q., Liu, D. L., and Junghans, R. P. (2010). Anti-CD3 GD3 chimeric sFv-DV28(T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16, 2769–2780.

Lucini, C., Vadovaldo, B., Dotti, G., Pule, M., Yoven, E., Myers, G. D., Rossig, C., Russell, H. V., Diouf, O., Liu, E., Liu, H., Wu, M. F., Gee, A. P., Mei, Z., Rooney, C. M., Heslop, H. E., and Brenner, M. K. (2011). Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050–6056.

Lucio, P., Gaipa, G., van Lochem, E. G., van Wering, E. R., Porwit-MacDonald, A., Faria, T., Bjorklund, E., Biondi, A., van den Beemd, M. W., Baars, E., Vidrias, B., Parreira, A., van Dongen, J. J., San Miguel, J. F., Orfao, A., and BIOMED-2. (2001). BIOMED-2 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 concerted action investigation of minimal residual disease in acute leukemia: international standardization and clinical evaluation. Leukemia 15, 1185–1192.

Luiten, R. M., Kuerer, E. W., Mooi, W., Gallez, M. P., Rankin, E. M., Gerritsen, W. R., Clift, S. M., Nooijen, W., J. C., Rosenberg, W. F., Sein, J., van den Berk, P. C., Nieweg, O. E., Berns, A. M., Spits, H., and de Gast, G. C. (2005). Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J. Clin. Oncol. 23, 8879–8891.

Majeti, R., Cho, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D. J., van Rooijen, N., and Weissman, I. L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299.

Matutes, E., Rodriguez, B., Polli, N., Tavares de Castro, J., Parreira, A., Andrews, C., Griffin, J. D., Tindle, W., and Coplan, K., Chen, Y. T., Stockert, E., Parreira, A., van Rooijen, N., and Weissman, I. L. (2009). CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138, 286–299.

Modak, S., Gerald, W., and Cheung, N. K. (2002). Disialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumor. Med. Pediatr. Oncol. 39, 547–551.

Modak, S., Kramer, K., Gultekin, S. H., Ho, H. F., and Cheung, N. K. (2001). Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 61, 4048–4054.

Möldrem, D., Dermine, S., Parker, K., Jiang, Y. Z., Mavroudis, D., Hensel, N., Fukushima, P., and Barrett, A. J. (1996). Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 88, 2450–2457.

Moog-Lutz, C., Degoutin, J., Gouzi, J. Y., Frobert, Y., Brunet-de Carvalho, N., Bureau, J., Créminon, C., and Vigny, M. (2005). Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin. J. Biol. Chem. 280, 26039–26048.
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurenz, C. M., and Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851.

Mosse, Y. P., Lautenslager, M., Longo, L., Cole, K. A., Wood, A., Attieh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, E., Laureys, G., Speleman, F., Kim, C., Hou, C., Hakonarson, H., Torkamani, A., Schork, N. J., Brodeur, G. M., Tonini, G. P., Rapaport, E., Devoto, M., and Maris, J. (2008). Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930–935.

Mulero, V., la Torre, A., Marinello, P., Rodriguez, R., Cardoso, J., Diaz, R., O’Farrill, M., Macias, A., Viada, C., Saurez, G., Carr, A., Crombet, T., Mazorra, Z., Perez, R., and Fernandez, L. E. (2010). Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: results from a controlled study in metastatic breast cancer patients. Hum. Vaccin. 6, 734–746.

Nagler, L. M., Anderson, K. C., Marti, G., Bates, M., Park, E., Boyd, A. W., Slaughenhourt, B., Park, J. R., Digiusto, D. L., Slovak, D. Y. (1997). Detection of anaplastic lymphoma kinase (ALK) in neuroblastoma pathogenesis. J. Clin. Oncol. 15, 825–833.

Nagno, N., Teipar, S., Morgillo, E., De Luca, A., Van Cutsem, E., and Cardello, F. (2009). Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 6, 519–527.

Oba-Shinjo, S. M., Caballero, O. L., Jungbluth, A. A., Rosenberg, S. G., Old, L. J., Simpson, A. J., and Marie, S. K. (2008). Cancer-tests (CT) antigen expression in medulloblastoma. Cancer Immun. 8, 7.

Oberthuer, A., Hero, B., Spitz, R., Berthold, F., and Fischer, M. (2004). The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 10, 4307–4315.

Ohmi, Y., Tajima, O., Obakawa, Y., Yamauchi, Y., Sugiru, Y., and Furukawa, K. (2011). Gangliosides are essential in the protection of neurogenesis and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice. J. Neurochem. 116, 926–935.

Okno, M., Natsume, A., Ichiyo Iwami, K., Iwamizou, H., Noritake, K., Itou, D., Toi, Y., Ito, M., Motoyama, K., Yoshida, J., Yoshikawa, K., and Wakabayashi, T. (2010). Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci. 101, 2518–2524.

Ohta, H., Hashii, Y., Yoneya, A., Takizawa, I., Kasukawa, T., Tokimas, S., Fukuzawa, M., Tsuibo, A., Murao, A., Oka, Y., Oji, Y., Aozasa, K., Nakatsuka, S., Sugiyama, H., and Ozono, K. (2009). WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr. Hematol. Oncol. 26, 74–83.

Olsen, S. K., Garbi, M., Zampieri, N., Eliseenkova, A. V., Orntz, D. M., Goldfarb, M., and Mohammadi, M. (2003). Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J. Biol. Chem. 278, 34226–34236.

Oshima, Y., Joshi, B. H., and Puri, R. K. (2008). Adoption transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15, 825–833.

Pastor, E., Colonias, D., McNamara Li, J. O. I., Gilboa, E. (2011). Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers. Mol Ther. 19, 1878–1886.

Paulson, V., Chandler, G., Rakheja, D., Galindo, R. L., Wilson, K., Amatruda, J. E., and Cameron, S. (2011). High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 50, 397–408.

Peppis, K. S., Quezada, S. A., Korman, A. J., and Allison, J. P. (2006). Prinicipals of type-IV anti-CTLA4 therapy in human cancer immunotherapy. Curr. Opin. Immunol. 18, 206–213.

Piccula, P. A., Arpinati, M., Candoni, A., Laterza, C., Paolini, S., Gazzola, S., Sabattini, E., Visani, G., and Pileri, S. A. (2010). Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia. Leuk. Lymphoma 52, 325–327.

Pollack, S. M., Loggers, E. T, Rodler, E. T., Yee, C., and Jones, R. L. (2011). Immune-based therapies for sarcoma. Sarcoma 2011, 438940.

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., and June, C. H. (2011). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733.

Pule, M. A., Savoldo, B., Myers, G. D., Rossig, C., Russell, H. V., Dotti, G., Huls, M. H., Liu, E., Gee, A. P., Mei, Z., Yvon, E., Weiss, H. L., Liu, H., Rooney, C. M., Heslop, H. E., and Brenner, M. K. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264–1270.

Pulford, K., Lamant, L., Morris, S. W., Butler, L. H., Wood, K. M., Stroud, D., Delsole, G., and Mason, D. Y. (1997). Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89, 1394–1404.

Quer, E. A., Cairo, M. S., Borowitz, M. J., Blaney, S. M., Krailo, M. D., Leil, T. A., Reid, J. M., Goldenberg, D. M., Wegener, W. A., Carroll, W. L., Adamson, P. C., and Children’s Oncology Group Pilot Study. (2008). Chemoimmunotherapry reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children’s Oncology Group Pilot Study. J. Clin. Oncol. 26, 3756–3762.

Ragab, S. M., Samaka, R. M., and Shams, T. M. (2010). HER2/neu expression: a predictor for differentiation and survival in children with Wilms tumor. Pathol. Oncol. Res. 16, 61–67.

Rappaport, A. P., Aguà, N. A., Stadtmayer, A. E., Vogl, D. T., Fang, H. B., Cai, L., Janofsky, S., Chew, A., Storek, J., Akpek, G., Badros, A., Yanovich, S., Tan, M. T., Veloso, E., Pasetti, M. F., Cross, A., Philip, S., Murphy, H., Bhagat, R., Zheng, Z., Milliton, T., Cesar, J., Cannon, A., Levine, B. L., Vanderheide, R. H., and June, C. H. (2011). Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 117, 788–797.

Ravindranath, M. H., Yesowitch, P., Sumobay, C. M., and Morton, D. L. (2007). Glycoimmunomics of human cancer: current concepts and future perspectives. Future. Oncol. 3, 201–214.

Rezvani, K. (2008). PRI vaccination in myeloid malignancies. Expert Rev. Vaccines 7, 867–875.

Ribas, A., and Fehlberg, K. T. (2011). BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426–433.

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helmam, L. J., Mackall, C. L., Kammula, U. S., Hughes, M. S., Restifo, N. P., Raffeld, M. Lee, C. C., Levy, C. L., Li, Y. F., El-Gamil, M., Schwarz, S. L., Laurenz, C., and Rosenberg, S. A. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917–924.

Rosenfeld, C., Cheever, M. A., and Guigcer, A. (2003). WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 17, 1301–1312.

Ross, J. F., Chaudhuri, P. K., and Ratnam, M. (1994). Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic
and clinical implications. Cancer 73, 2432–2443.

Russell, L. J., Capasso, M., Vater, I., Akasaka, T., Bernard, O. A., Calasanz, M. J., Chandrasekaran, T., Chapiro, E., Gek, S., Griffiths, M., Guttery, D. S., Haferlach, C., Harder, L., Heidenreich, O., Irving, J., Kearney, L., Nguyen-Khac, F., Machado, L., Minto, I., Majid, A., Moorman, A. V., Morrison, H., Rand, V., Strefford, J. C., Schwab, C., Tönnies, H., Dyer, M. J., Siebert, R., and Harrison, C. J. (2009). Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114, 2688–2698.

Saikali, Z., and Sinnett, D. (2000). Expression of gliapican (GPI1) in embryonal tumors. Int. J. Cancer 89, 418–422.

Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E. II, McLendon, R. E., Mitchell, D. A., Reardon, D. A., Sawaya, N., Schmittling, R. J., Shi, W., Vredenburgh, J. J., and Bigner, D. D. (2010). Immunologic escape after prolonged progression-free vaccination with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722–4729.

Schindler, J., Gajavelli, S., Ravanelli, F., Shen, Y., Varek, S., Braunschweig, I., Barta, S., Ghetie, V., Vitetta, E., Shiu, M., S., Pozzo, N., Gabri, M. R., de Palmi, C., Ganmore, I., te Kronrique, M. U., and Izraeli, S. (2011). Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 208, 901–908.

Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Balfour, J., and Bardelli, A. (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101, 1308–1324.

Smith, M. R. (2003). Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22, 7559–7568.

Spanakos, A., Perdikogianni, C., Linardakis, E., and Kalaminti, M. (2007). Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia. Leuk. Res. 31, 639–642.

Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O’Bryant, C., Chow, L. Q., Sarkova, N. J., Meropol, N. J., Lewis, N. L., Chiorini, E. G., Fox, E., Voumidan, H., Rowinsky, E. K., and Eckhardt, S. G. (2010). Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J. Clin. Oncol. 28, 780–787.

Stasi, R., Papano, A., Stipa, E., and Amadori, S. (2001). Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98, 1529–1535.

Stein, H., Mason, D. Y., Gerdes, J., O’Connor, N., Wainscoat, J., Palle, S., Gatter, K., Falini, B., Del-sol, G., and Lemke, H. (1985). The expression of the Hodgkin’s disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and hematolymphoid malignancies are derived from activated lymphoid cells. Blood 66, 848–858.

Steinbach, D., Schramm, A., Eggert, A., Onda, M., Dawczynski, K., Rump, A., Pasan, I., Wittig, S., Pfaffendorf, N., Voigt, A., Zintl, F., and Gruhn, B. (2006). Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin. Cancer Res. 12, 2434–2441.

Steinbach, D., Viehmeh, S., Zintl, F., and Gruhn, B. (2002). PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 138, 89–91.

Stone, M. J., Sausville, E. A., Fay, J. W., Headler, D., Collins, R. H., Figg, W. D., Steoler-Stevenson, M., Jain, V., Jaffe, E. S., Solomon, D., Lush, R. M., Senderowitz, A., Ghetie, V., Schindler, I., Uhr, J. W., and Vitetta, E. S. (1996). A Phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG1-Fc-D3-lgA, in patients with B-cell lymphoma. Blood 88, 1188–1197.

Suzuki, H., Onishi, H., Wada, I., Yamasaki, A., Tanaka, H., Nakano, K., Morisaki, T., and Katano, M. (2010). VEGFR2 is selectively expressed by CD70-positive malignancies. Cancer Res. 70, 952–957.

Tang, S. C., Hewitt, K., Reis, M. D., and Bernstein, N. L. (1996). Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk. Lymphoma 24, 93–101.

Taylor, J. G. V., Cheuk, A. T., Tsang, P. S., Chung, J. Y., Song, Y. K., Desai, K., Yu, Y., Chen, Q. R., Shah, K., Youngblood, V., Fang, J., Kim, S. M., Yeung, C., Helman, L. I., Mendoza, A., Ngo, V., Staudt, L. M., Wei, J. S., Khanna, C., Catchpole, D., Qualman, S. J., Hewitt, S. M., Merlino, G., Chanock, S. J., and Khan, J. (2009). Identification of FGR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 119, 1560–1570.
genomic hybridization. J. Neurosurg. 100, 187–193.
Topp, M. S., Kufer, P., Godbolet, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H. A., Rafl, T., Viadot, A., Schmid, M., Stelljes, M., Schait, M., Degenhard, E., Köhne-Volland, R., Brüggemann, M., Ottmann, O., Pfeifer, H., Burmeister, T., Nagorsen, D., Schmidt, M., Lutterbuese, R., Reinhardt, C., Baurelle, P. A., Kneba, M., Ensele, H., Riethmüller, G., Hoelzer, D., Zugmaier, G., and Bargou, R. C. (2011). Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29, 2493–2498.
Turk, M. J., Wolchok, J. D., Guevara-Patino, J. A., Goldberger, S. M., and Houghton, A. N. (2002). Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188, 122–135.
Urbà, T. J., and Longo, D. L. (2011). Redirecting T cells. N. Engl. J. Med. 365, 754–757.
Vallera, D. A., Chen, H., Sithener, A. R., Panoskaltsis-Mortari, A., and Taras, E. P. (2009). Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk. Res. 33, 1233–1242.
van den Broeke, L. T., Pendleton, C. D., Mackall, C., Helman, L. J., and Berzofsky, J. A. (2006). Identification and epitope enhancement of a PAX-FKH fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res. 66, 1818–1823.
Vulcani-Freitas, T. M., Saba-Silva, N., Cappellano, A., Cavaleiro, S., and Toledo, S. R. (2011). PRAME gene expression profile in medulloblastoma. Ang. Neuropsiquiatr. 96, 9–12.
Wayne, A., Bohjwani, D., Silverman, L. B., Richards, K., Steller-Stevenson, M., Shah, N. N., Jicha, S., Pui, C., Buzioanu, M., FitzGerald, D. J., Keitman, R. J., Ibrahim, R., and Pastan, I. (2011). A novel anti-CD22 immunotoxin, monoketomab pasudotox: phase I study in pediatric acute lymphoblastic leukemia (ALL), in ASH Annual Meeting Abstracts, San Diego, CA, 248.
Weyn, T. R., Slavish, J., George, R. E., Look, A. T., Xue, L., Jiang, Q., Cui, X., Rentrop, W. B., and Morris, S. W. (2009). Anaplastic lymphoma kinase: role in cancer pathogenesis and small molecule inhibitor development for therapy. Expert Rev. Anticancer Ther. 9, 331–356.
Weinstein, J. B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68, 3077–3080; discussion 80.
Wellstein, A., and Toretsky, J. A. (2011). Hunting ALK to feed targeted cancer therapy. Nat. Med. 17, 290–291.
Weschke, J., Haglund, K., and Hausteg, E. M. (2011). Fibroblast growth factors and their receptors in cancer. Biochem. J. 437, 199–213.
Williams, D., Selfe, I., Gordon, T., Lu, Y. I., Pritchard-Jones, K., Murai, K., Jones, P., Workman, P., and Shipley, J. (2007). Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res. 67, 57–65.
Wischhusen, J., Jung, G., Radovanovic, L., Beier, C., Steinbach, J. P., Rimmer, N., Huang, H., Schulz, J. B., Ohlaki, H., Aguzzi, A., Ramnemese, H. G., and Weller, M. (2002). Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res. 62, 2582–2599.
Witzig, T. E., Fishkin, P., Gordon, L. L., Gregory, S. A., Jacobs, S., Macklis, R., McLaughlin, P., Press, O., and Zelezn, A. D. (2011). Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk. Lymphoma 52, 1188–1199.
Worley, B. S., van Broeke, L. T., Goletz, T. J., Pendleton, C. D., Daschbach, E. M., Thomas, E. K., Marincola, F. M., Helman, L. J., and Berzofsky, J. A. (2001). Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 61, 6688–6675.
Wortzel, R. D., Phillips, C., and Schreiber, H. (1983). Multiple tumour-specific antigens expressed on a single tumour cell. Nature 304, 165–167.